While cost discipline improved non-GAAP losses and extended cash runway, the lack of revenue growth and continued net losses raise sustainability concerns. Upcoming 2026 clinical data readouts for vispa-cel and CB-011 will be critical catalysts. Investors should monitor whether Caribou secures additional funding ahead of the vispa-cel pivotal trial.
CRBU drugs
CRBU drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 6 $1.82entry
- T+1 · 8mo ago +8.24%α +7.40% · $1.97
- T+5 · 8mo ago +3.30%α +4.83% · $1.88
- T+20 · 8mo ago +7.14%α +9.19% · $1.95
- T+60 · 6mo ago +33.52%α +20.74% · $2.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Caribou Biosciences reported fourth quarter and full-year 2025 financial results, highlighting clinical progress in its two allogeneic CAR-T programs, vispa-cel and CB-011, with upcoming data readouts expected in 2026. Revenue increased modestly, while R&D and G&A expenses declined due to workforce reductions and pipeline prioritization. The company reported a GAAP net loss of $148.1 million, including a $21.3 million non-cash impairment charge, and ended the year with $142.8 million in cash, sufficient to fund operations into 2H 2027.
Key Financial Metrics
Key Facts
- Licensing and collaboration revenue increased to $11.2 million in 2025 from $10.0 million in 2024.
- R&D expenses decreased to $109.4 million in 2025 from $130.2 million in 2024 due to cost-cutting measures.
- GAAP net loss was $148.1 million in 2025, slightly improved from $149.1 million in 2024.
- Non-GAAP net loss improved to $126.8 million in 2025 from $149.1 million in 2024, excluding $21.3 million in non-cash impairment charges.
- Cash, cash equivalents, and marketable securities declined to $142.8 million from $249.4 million at year-end 2024.
- Company expects cash runway into 2H 2027 but is exploring options to fully fund the planned vispa-cel pivotal trial.
- Longer follow-up data from ANTLER trial and initial dose expansion data for CB-011 expected in 2026.
Financial Impact
Revenue up 12% YoY to $11.2M; operating expenses down $17.1M; cash burn of $106.6M in 2025; $21.3M non-cash impairment charge.
Risk Factors
- High cash burn and declining cash reserves despite cost-cutting; may require dilutive financing.
- Reliance on upcoming clinical data to validate 'best-in-class' claims without head-to-head trials.
- Forward-looking statements carry significant risk given early-stage pipeline and regulatory uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250668 |
Track record
13 reports on CRBU
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +28.02% at T+20 after the Oct 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
- Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
- Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
- Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Mar 5, 202636w ago Press Release Mixed 6/10 Viewing Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers